OPEN ACCESS PLUS

Accepted articles are published online for free open access for all to view. Open access publishing provides the maximum dissemination of the article to the largest audience. Authors must pay for this service. All corresponding authors will be asked to indicate whether or not they wish to pay to have their paper made freely available on publication. If authors do not select the Open Access option, then their article will be published with standard subscription-based access at no charge.

Authors who opt for Open Access Plus may also self-archive publishers postprints. Bentham Science is compliant with the open access policy for the  MRC, Cancer Research UK, NIH, and many other funders. For details, refer to  http://www.benthamscience.com/permission.php or email to; openaccess@benthamscience.org.

cGMP Signaling, Phosphodiesterases and Major Depressive Disorder Pp. 715 - 727 Gillian W. Reierson, Shuyu Guo, Claudio Mastronardi, Julio Licinio and Ma-Li Wong [View Abstract] [Open Access Plus]

Deficits in neuroplasticity are hypothesized to underlie the pathophysiology of major depressive disorder (MDD): the effectiveness of antidepressants is thought to be related to the normalization of disrupted synaptic transmission and neurogenesis. The cyclic adenosine monophosphate (cAMP) signaling cascade has received considerable attention for its role in neuroplasticity and MDD. However components of a closely related pathway, the cyclic guanosine monophosphate (cGMP) have been studied with much lower intensity, even though this signaling transduction cascade is also expressed in the brain and the activity of this pathway has been implicated in learning and memory processes. Cyclic GMP acts as a second messenger; it amplifies signals received at postsynaptic receptors and activates downstream effector molecules resulting in gene expression changes and neuronal responses. Phosphodiesterase (PDE) enzymes degrade cGMP into 5GMP and therefore they are involved in the regulation of intracellular levels of cGMP. Here we review a growing body of evidence suggesting that the cGMP signaling cascade warrants further investigation for its involvement in MDD and antidepressant action.